Biovie Inc recorded a cumulative net loss of $-22 million during 12 month ending in the fourth quarter 2026.
The Healthcare sector has seen employees of 300 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3917, from total ranking in previous quarter at 3992.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BIVI Net Income per Employee	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-1,697,913	-1,532,036	-1,341,121	-1,421,356	-1,349,392
BIVI's Total Ranking	# 3917	# 3992	# 3139	# 3211	# 3151
Seq. Net Income Change	-	-	-	-	-

BIVI Company Profile >> Back to BIVI Efficiency Comparisons >> Compare BIVI Net Income per Employee to its Competitors

BIVI Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 301
Healthcare Sector	# 721
Overall Market	# 3917

Net Income per Employee Statistics
High	Average	Low
$ 4,122,948	$ -1,023,127	$ -5,873,733
(Jun 30 2021)		(Jun 30 2023)

News about Biovie Inc Income per employee

BioVie Inc. Announces Pricing of Public Offering

BioVie Inc. Announces Pricing of Public Offering: A Strategic Step Towards Revolutionizing Treatment for Chronic Diseases Amid Financial ChallengesIn recent developments, BioVie Inc. (NASDAQ: BIVI), a clinical-stage enterprise at the forefront of innovative therapeutics for chronic debilitating conditions, including advanced liver disease and neurodegenerative disorders, has taken a significant financial step forward. On September 23, 2024, the company announced the pricing for a best efforts public offering encompassing 1,960,800 shares of its common stock and warrants to purchase a similar number of common shares. Each share or pre-funded warrant is being offered at a combined price of $1.53, with associated warrants possessing an exercise price of $1.53 per share and immediate exercisability for five years following issuance.The anticipated gross proceeds from this offering are projected to reach approximately $3 million, a vital influx of capital against the backdrop of notable financial challenges faced by the company. BioVie’s decision to embark on this public offering reflects a dual focus: to shore up its financial standing while advancing clinical research aimed at transforming treatment paradigms in areas of significant unmet need.

BioVie Inc. Pursues Capital with Public Offering Amid Flourishing Prospects in Long COVID Treatment,

BioVie Inc. Pursues Growth Amidst Financial Challenges and Promising Clinical DevelopmentsIn an intricate dance of opportunity and risk, BioVie Inc. (NASDAQ: BIVI) finds itself at a pivotal moment in its journey as a clinical-stage company that aims to revolutionize treatment for advanced liver disease and neurodegenerative disorders. The recent announcements from the company shed light on its strategic efforts to secure funding while grappling with significant financial losses.The Public Offering ChallengeBioVie recently declared its intention to conduct a best-efforts public offering of its common stock and accompanying common stock purchase warrants. The timing of such a move is critical, particularly as the company reported a cumulative net loss of $37 million for the 12 months ending in the third quarter of 2023. This figure not only indicates the financial strains the company has been facing, but also underscores the urgency to raise capital to support its ambitious clinical research and operational activities. The magnitude of the losses suggests that potential investors will closely scrutinize BioVie’s fiscal health and long-term viability, particularly in light of the volatile landscape of biotech investments.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-02T19:07:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.